Mariner
MYGN icon

Mariner’s Myriad Genetics MYGN Stock Holding History

Mariner’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
97,276
+45,384
+87% +$206K ﹤0.01% 2380
2026
Q1 		$233K Buy
51,892
+3,726
+8% +$19.4K ﹤0.01% 3068
2025
Q4 		$296K Buy
48,166
+19,522
+68% +$142K ﹤0.01% 2859
2025
Q3 		$207K Buy
28,644
+16,794
+142% +$99.7K ﹤0.01% 3147
2025
Q2 		$62.9K Buy
+11,850
New +$70K ﹤0.01% 3313
2024
Q4 		– Sell
-17,490
Closed -$479K – 3476
2024
Q3 		$479K Buy
17,490
+621
+4% +$16.8K ﹤0.01% 2157
2024
Q2 		$412K Buy
16,869
+1,206
+8% +$26.5K ﹤0.01% 2192
2024
Q1 		$334K Buy
15,663
+837
+6% +$18K ﹤0.01% 2349
2023
Q4 		$284K Sell
14,826
-869
-6% -$15K ﹤0.01% 2398
2023
Q3 		$252K Sell
15,695
-1,188
-7% -$22.6K ﹤0.01% 2308
2023
Q2 		$391K Sell
16,883
-1,636
-9% -$35.7K ﹤0.01% 1918
2023
Q1 		$430K Buy
18,519
+864
+5% +$17.5K ﹤0.01% 1784
2022
Q4 		$256K Sell
17,655
-1,877
-10% -$35K ﹤0.01% 2161
2022
Q3 		$373K Buy
19,532
+5,051
+35% +$116K ﹤0.01% 1618
2022
Q2 		$263K Buy
14,481
+154
+1% +$3.2K ﹤0.01% 1318
2022
Q1 		$361K Buy
+14,327
New +$367K ﹤0.01% 1237

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mariner's MYGN Position: Q2 2026 in Review

Mariner increased its Myriad Genetics (MYGN) stake by 87% in Q2 2026, buying an estimated $206K and bringing the position to 97,276 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Mariner first reported a position in MYGN in Q1 2022 and has held it in 16 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Mariner held 97,276 shares of Myriad Genetics worth $555K as of Q2 2026.
  • Mariner bought 45,384 Myriad Genetics shares in Q2 2026, an estimated $206K.
  • Myriad Genetics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2380 holding.
  • Mariner first reported a position in Myriad Genetics in Q1 2022 and has held it in 16 quarters since.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.